Xeris Biopharma Holdings Overview

Xeris Biopharma Holdings Cost of Revenue

Cost of Revenue analysis for XERS.

Quarterly Cost of Revenue

N/A

As of Mar 31, 2026

Annual Cost of Revenue (TTM)

$27.81M

↑ 52.74% YoY

Trailing 12 months ending Mar 31, 2026

Average Cost of Revenue (Comparison Companies)

Cost of Revenue History

Cost of Revenue Comparison

Annual Cost of Revenue Growth Rate (%)

Annual Cost of Revenue Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin